ArticleInternational journal of bipolar disorders2025
Antipsychotic use in bipolar disorder: clinical and genomic correlates- a Mayo clinic bipolar disorder biobank study.
Article in International journal of bipolar disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- The anxious bipolar phenotype: clinical complexity and treatment response.International journal of bipolar disorders · 2026Article
- The Anxious Bipolar Phenotype: Clinical Complexity and Treatment Resistance.Research square · 2026Article
- Sodium-glucose cotransporter-2 inhibitors lower risk of kidney replacement therapy and mortality in bipolar disorder with chronic kidney disease.Therapeutic advances in psychopharmacology · 2026Article
Corrections and comments
- Update of
Authors and funding
15 authors.
Funding
Abstract
backgroundResponsiveness to mood-stabilizing pharmacotherapy varies in bipolar disorder (BD). We investigated clinical correlates of second-generation antipsychotic (SGA) treatment response and conducted the first genome-wide association study (GWAS), including exploratory polygenic scores (PGS), of SGA pharmacogenomic treatment response in BD.
methodsTreatment response was quantified using the Alda scale, and GWAS was performed using Alda-A score, controlling for sex, genotyping batch, and the genomic principal components.
resultsThe cohort included 2,159 adults with BD (1,416 BD-I, 691 BD-II, 51 schizoaffective BD), mean age 41.8 years, 62% female, 84% white, and 14% Hispanic. Nearly half (48%) were treated with SGAs. Current SGA users were younger (41.2 ± 14.7 vs. 42.5 ± 15.3 years, p = 0.040), more likely to be Hispanic (14% vs. 11%, p = 0.047), had a higher body mass index (BMI; 30.4 ± 7.6 vs. 29.5 ± 7.1 kg/m
conclusionsSGAs are frequently utilized as mood stabilizers in patients with BD and are associated with manic psychosis and eating disorders. GAS7 variants may predict SGA response, but larger, more diverse cohorts are needed for validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.